IRIS
PUPPO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.205
Totale 15.205
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.205
Totale 15.205
Salva come PNG Salva come JPEG
Città #
Genova 12.123
Rapallo 1.549
Genoa 1.204
Vado Ligure 287
Bordighera 42
Totale 15.205
Salva come PNG Salva come JPEG
Nome #
Infection risk associated with anti-TNF-α agents: A review 166
Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. 157
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 151
Vaccine-preventable infections in Systemic Lupus Erythematosus 143
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 140
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 140
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 139
The antiphospholipid syndrome: from pathophysiology to treatment 137
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 136
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 136
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 136
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 135
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 134
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 132
Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro 129
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 129
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 127
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 126
Immunoregulatory Role of HLA-G in Allergic Diseases 126
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 126
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 125
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. 125
General surgery, translational lymphology and lymphatic surgery 124
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients 123
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 122
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 119
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 118
In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? 117
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 117
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes 116
Immune cell circulating subsets are affected by gonadal function. 116
Fas, Fas ligand, and transfusion immunomodulation 116
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 115
Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions. 114
Effect of levamisole on postoperative immunosuppression 114
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 114
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 113
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 113
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 113
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 113
Potential use of TNF-α inhibitors in systemic sclerosis. 113
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort 112
Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. 111
Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction 111
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 111
Immunoglobulin production pattern is allergen-specific in polysensitized patients. 110
Deficiency of the autologous mixed lymphocyte reactions of non-T/T and T/T type in intravenous drug abusers infected by the human immunodeficiency virus (HIV). 108
Current views on diagnostic approach and treatment of lymphedema 108
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 107
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 107
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. 105
Defective expression and function of the leukocyte associated ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients 105
Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. 105
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 104
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 103
Serum zinc levels in patients with multiple myeloma ad waldenstrom's disease 102
Serum HLA class I antigens: markers and modulators of an immune response? 102
Immunohistochemical evidnce of HLA-G expression in extravillous trophoblast invading decidual tissues. 102
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 102
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 102
Immune homeostasis requires several biologic factors including glucocorticoid hormones 102
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. 101
Genetic factors and systemic sclerosis 101
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 100
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 100
Efficacy and safety of etanercept in chronic immune-mediated disease. 100
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 100
null 99
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 99
DsDNA-specific T-cell lines in systemic lupus erythematosus patients: data suggesting their oligoclonality. 98
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 98
FRI0199 EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 97
Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. 96
Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. 96
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 96
CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function. 96
Update upon efficacy and safety of TNF-α inhibitors. 96
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily 95
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 95
Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. 95
Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. 95
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. 95
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 95
An Uncommon Presentation of Pancreatic Carcinoma 95
Endothelial dysfunction in rheumatic autoimmune diseases. 95
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 94
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 93
Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. 93
A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. 93
Soluble HLA antigens: new roles and uses 92
null 92
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 92
Update upon the infection risk in patients receiving TNF alpha inhibitors 92
Emerging biologic drugs for the treatment of rheumatoid arthritis 91
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 91
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment 91
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. 91
HLA-G Expressing Immune Cells in Immune Mediated Diseases 91
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 89
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? 88
Totale 11.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.579
article - articoli 44.299
book - libri 358
conference - conferenze 403
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 519
Totale 91.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.029 0 0 205 285 392 504 673 306 360 710 461 133
2020/20211.307 77 130 122 161 75 134 77 102 100 130 82 117
2021/20222.013 60 166 134 238 60 128 121 479 90 181 100 256
2022/20231.840 167 109 31 188 319 331 2 143 313 13 198 26
2023/2024909 33 162 13 107 64 146 79 71 52 8 56 118
2024/2025359 103 210 46 0 0 0 0 0 0 0 0 0
Totale 15.466